Ballentine Partners’s CureVac CVAC Stock Holding History

Ballentine Partners’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,357	Closed	-$160K	–	1031
2025 Q4	$160K	Sell	35,357 -2,447	-6%	-$12.5K	﹤0.01%	941
2025 Q3	$204K	Hold	37,804	–	–	﹤0.01%	909
2025 Q2	$205K	Buy	37,804 +6,231	+20%	+$24.7K	﹤0.01%	874
2025 Q1	$87.5K	Buy	31,573 +14,210	+82%	+$49.4K	﹤0.01%	862
2024 Q4	$58.6K	Sell	17,363 -5,392	-24%	-$15.5K	﹤0.01%	867
2024 Q3	$66.9K	Buy	22,755 +8,406	+59%	+$27.7K	﹤0.01%	817
2024 Q2	$48.8K	Buy	14,349 +1,752	+14%	+$5.73K	﹤0.01%	745
2024 Q1	$38.2K	Buy	+12,597	New	+$44.2K	﹤0.01%	731

Ballentine Partners's CVAC Position: Q1 2026 in Review

Ballentine Partners sold out of CureVac (CVAC) in Q1 2026, closing a stake of 35,357 shares — an estimated $160K sold.

Ballentine Partners first reported a position in CVAC in Q1 2024 and held it in 8 quarters. The position peaked at $205K in Q2 2025. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.

Ballentine Partners reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
Ballentine Partners sold 35,357 CureVac shares in Q1 2026, an estimated $160K.
Ballentine Partners first reported a position in CureVac in Q1 2024 and held it in 8 quarters.
Ballentine Partners's CureVac position peaked at $205K in Q2 2025.
0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.

Based on Ballentine Partners's 13F filing for Q1 2026, filed 14 May 2026.